Last Updated: September 28, 2026

Details for Patent: 8,592,450


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,592,450 protect, and when does it expire?

Patent 8,592,450 protects XIIDRA and is included in one NDA.

This patent has thirty-five patent family members in fifteen countries.

Summary for Patent: 8,592,450
Title:Compositions and methods for treatment of eye disorders
Abstract:The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Inventor(s):Thomas Gadek, John Burnier
Assignee: Bausch and Lomb Ireland Ltd
Application Number:US13/398,542
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,592,450
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Device; Dosage form;

Drugs Protected by US Patent 8,592,450

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,592,450

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2444079 ⤷  Start Trial C02444079/01 Switzerland ⤷  Start Trial
Australia 2006247136 ⤷  Start Trial
Canada 2609053 ⤷  Start Trial
Canada 2960117 ⤷  Start Trial
Canada 2985444 ⤷  Start Trial
China 101175488 ⤷  Start Trial
China 102617557 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.